Naohiro Fujimoto

14PUBLICATIONS
29CO-AUTHORS
Oncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targets
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (14)

|Jan 09, 2024
Clinicopathological characteristics of adrenocortical carcinoma in the Kyushu-Okinawa area of Japan.

|Dec 26, 2023
GnRH antagonist monotherapy versus a GnRH agonist plus bicalutamide for advanced hormone-sensitive prostate cancer; KYUCOG-1401.

Akira Yokomizo, Masaki Shiota, Futoshi Morokuma

|Jun 22, 2023
Efficacy and safety of pembrolizumab and axitinib as first-line treatment for patients with advanced renal cell carcinoma: Real-world experience in Japan.

Ken-Ichi Harada, Ryo Sato, Yukari Bando

|Jan 24, 2023
Differential impact of proton pump inhibitor on survival outcomes of patients with advanced urothelial carcinoma treated with chemotherapy versus pembrolizumab.

Ikko Tomisaki, Mirii Harada, Shigeru Sakano

|Nov 17, 2022
The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status.

Nobuki Furubayashi, Akinori Minato, Takahito Negishi

|May 31, 2022
Comprehensive assessments of immuno-oncology drug-based combination therapies as first-line treatment for advanced renal cell carcinoma.

Ken-Ichi Harada, Hideaki Miyake, Junya Furukawa

Pageof 3

Frequent Collaborators

4 joint publications

Masaki Shiota

4 joint publications

Kenichi Harada

3 joint publications

Toshihisa Tomoda

3 joint publications

Nobuki Furubayashi